Effect of Nivolumab Combined with Vinorelbine and Cisplatin Regimen in Patients with Non-small Cell Lung Cancer
Objective To investigate the effect of nivolumab combined with vinorelbine+cisplatin regimen in patients with non-small cell lung cancer(NSCLC).Methods This study used a prospective randomized controlled analysis and included 86 NSCLC patients admitted to Pingmei Shenma Medical Group General Hospital from June 2020 to June 2022 as the study subjects.According to the random number table method,they were divided into a control group and an observation group,with 43 patients in each group.Patients in the control group were treated with vinorelbine+cisplatin regimen,and the patients in the observation group were treated with nivolumab on this basis,3 weeks as a cycle.The patients in both groups were treated for 3 cycles and followed up for 6 months.The clinical efficacy after treatment,the levels of serum tumor markers,vascular endothelial growth factor(VEGF)and T lymphocyte subsets before and after treatment were compared between the two groups,and the progression-free survival(PFS)and toxic and side effects were recorded.Results After 3 courses of treatment,the disease control rate in the observation group was higher than that in the control group(P＜0.05).There was no significant difference in the objective remission rate between the two groups(P＞0.05).After treatment,the levels of various tumor markers and VEGF in both groups decreased,with the observation group showing a more significant decrease(P＜0.05).After treatment,the levels of CD4+,CD4+/CD8+,and CD3+in both groups increased,while the level of CD8+decreased,with the observation group showing greater changes(P＜0.05).There was no significant difference in the rate of toxic side effects between two groups(P＞0.05).Conclusion Nivolumab combined with vinorelbine and cisplatin regimen chemotherapy has a good effect in patients with advanced NSCLC,which can effectively regulate the levels of tumor markers and VEGF,improve the immune function of patients,prolong the progression free survival time,and do not increase the side effects.
NETL
NSTL
万方数据
